Ashish Ranjan, Director, Kotak Alternate Asset Managers Limited, India, says early stage nutraceutical adoption offers long term growth potential
INR 400 Million Investment from Kotak Alts Fuels Zeroharm Sciences Expansion
Mumbai, February 18, 2026: Kotak Alternate Asset Managers Limited, through its Kotak Life Sciences Fund I, has invested INR 400 million in Zeroharm Sciences, a plant based nutraceutical direct to consumer brand founded in 2020.
Sachin Darbarwar, Co Founder and Chief Executive Officer, Zeroharm Sciences, India, said, “This investment marks a transition from early product validation to scaled growth. Partnering with Kotak Alts and Alkemi Growth Capital provides not only capital but long term institutional support. Their understanding of the healthcare and life sciences ecosystem aligns with our integrated model across extraction, formulation, research and manufacturing.”
Alkemi Growth Capital partnership Zeroharm India Prittle Prattle News Ashish Ranjan Director Kotak Alts India statement PP News Ayurveda based nutraceutical technology integration India PP News Business news India life sciences February 2026 Prittle Prattle News Consumer health product scale up India PP News Direct to consumer nutraceutical platform India Smruti Bhalerao Early stage healthcare investment India PP News Healthcare ecosystem investment India PP News Healthcare growth capital India February 2026 PP News India plant based supplement brand funding PP News India preventive healthcare startup funding 2026 PP News India startup funding healthcare sector 2026 Smruti Bhalerao India wellness supplement market expansion PP News INR 400 million life sciences fund investment India 2026 PP News Integrated extraction formulation manufacturing model Smruti Bhalerao Kotak Alternate Asset Managers investment Zeroharm Sciences Prittle Prattle News Kotak Alts early growth stage investment Prittle Prattle News Kotak Alts healthcare investment strategy PP News Kotak Life Sciences Fund I portfolio expansion Prittle Prattle News Life sciences private equity investment India Prittle Prattle News Mumbai business investment announcement February 2026 PP News Nutraceutical market growth India 2026 PP News Plant based nutraceutical D2C brand India Smruti Bhalerao Private capital healthcare innovation India Smruti Bhalerao Sachin Darbarwar CEO Zeroharm Sciences India funding update Smruti Bhalerao Science led nutraceutical brand India Prittle Prattle News Smruti Bhalerao coverage Kotak Alts investment PP News Venture funding life sciences India 2026 Smruti Bhalerao Zeroharm Sciences D2C brand growth India PP News Zeroharm Sciences expansion international markets Prittle Prattle News
Comments
-
[…] INR 1,000 crore and later indicated a target size of INR 1,500 crore before strong investor commitments led to the upward revision.The Tristar Fund is positioned as a growth stage private equity strategy […]
Leave a Reply